Literature DB >> 24652496

Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Sita Awasthi1, Robert B Belshe2, Harvey M Friedman1.   

Abstract

The Herpevac Trial evaluated a herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) subunit vaccine to prevent genital herpes. Unexpectedly, the vaccine protected against genital HSV-1 infection but not genital HSV-2 infection. We evaluated sera from 30 women seronegative for HSV-1 and HSV-2 who were immunized with gD2 in the Herpevac Trial. Neutralizing antibody titers to HSV-1 were 3.5-fold higher than those to HSV-2 (P < .001). HSV-2 gC2 and gE2 on the virus blocked neutralization by gD2 antibody, while HSV-1 gC1 and gE1 did not block neutralization by gD2 antibody. The higher neutralizing antibody titers to HSV-1 offer an explanation for the Herpevac results, and shielding neutralizing domains provides a potential mechanism.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HSV-1; HSV-2; Herpevac Trial; glycoprotein C; glycoprotein D; glycoprotein E; neutralizing antibody; vaccine

Mesh：

Substances：

Year:  2014        PMID： 24652496      PMCID： PMC4172040          DOI： 10.1093/infdis/jiu177

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  14 in total

1.  Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.

Authors:  J C Whitbeck; C Peng; H Lou; R Xu; S H Willis; M Ponce de Leon; T Peng; A V Nicola; R I Montgomery; M S Warner; A M Soulika; L A Spruce; W T Moore; J D Lambris; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Herpes simplex virus type 1 glycoprotein e is required for axonal localization of capsid, tegument, and membrane glycoproteins.

Authors:  Fushan Wang; Waixing Tang; Helen M McGraw; Jean Bennett; Lynn W Enquist; Harvey M Friedman
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Oligomeric structure of glycoproteins in herpes simplex virus type 1.

Authors:  C G Handler; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons.

Authors:  Fushan Wang; Elizabeth E Zumbrun; Jialing Huang; Huaxin Si; Lena Makaroun; Harvey M Friedman
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

5.  Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.

Authors:  Lauren M Hook; John M Lubinski; Ming Jiang; Michael K Pangburn; Harvey M Friedman
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Authors:  Robert B Belshe; Thomas C Heineman; David I Bernstein; Abbie R Bellamy; Marian Ewell; Robbert van der Most; Carolyn D Deal
Journal:  J Infect Dis       Date:  2013-11-27       Impact factor: 5.226

7.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

8.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

9.  Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.

Authors:  Lauren M Hook; Jialing Huang; Ming Jiang; Richard Hodinka; Harvey M Friedman
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection.

Authors:  Kara A Judson; John M Lubinski; Ming Jiang; Yueh Chang; Roselyn J Eisenberg; Gary H Cohen; Harvey M Friedman
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103
View more
  32 in total

Review 1.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

Review 2.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

3.  Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"

Authors:  Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

4.  Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.

Authors:  Tina M Cairns; Zhen-Yu Huang; John R Gallagher; Yixin Lin; Huan Lou; J Charles Whitbeck; Anna Wald; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

5.  Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D.

Authors:  J Charles Whitbeck; Zhen-Yu Huang; Tina M Cairns; John R Gallagher; Huan Lou; Manuel Ponce-de-Leon; Robert B Belshe; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

6.  Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.

Authors:  Elena Criscuolo; Matteo Castelli; Roberta A Diotti; Virginia Amato; Roberto Burioni; Massimo Clementi; Alessandro Ambrosi; Nicasio Mancini; Nicola Clementi
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

7.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

8.  A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.

Authors:  Derek J Royer; Hem R Gurung; Jeremy K Jinkins; Joshua J Geltz; Jennifer L Wu; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

9.  Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Authors:  Sita Awasthi; Jialing Huang; Carolyn Shaw; Harvey M Friedman
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

10.  The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.

Authors:  Derek J Royer; Meghan M Carr; Hem R Gurung; William P Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2017-07-31       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.